LRRK2 deficiency mitigates amyloid β deposition-mediated pathology in a murine Alzheimer's disease model by

Qiuyang Zhang1,2, Hsuan Lo3,4, Yue Song2,5

  • 1Department of Neurology, Fuzhou Second General Hospital, 47 Shangteng Road, Fuzhou, 350007, China.

Translational Psychiatry
|October 6, 2025
PubMed

Insights

Leucine-rich repeat kinase 2 (LRRK2) deficiency improved cognitive function and reduced amyloid plaques in Alzheimer

Area of Science:

  • Neuroscience
  • Immunology
  • Genetics

Background:

  • Leucine-rich repeat kinase 2 (LRRK2) is implicated in innate immunity and neurological disorders.
  • LRRK2 mutations are linked to Parkinson's disease; its role in Alzheimer's disease (AD) immunopathogenesis is unclear.
  • LRRK2 polymorphism may be associated with late-onset AD.

Purpose of the Study:

  • To investigate the impact of LRRK2 deficiency on cognitive function, amyloid-beta (Aβ) plaque accumulation, and neuropathology in AD mice.
  • To explore how LRRK2 absence affects microglial responses and synaptic integrity in an AD mouse model.

Main Methods:

  • Utilized 5xFAD transgenic mice with and without LRRK2 deficiency (5xFAD;LRRK2-/-).
  • Assessed cognitive function using the Morris water maze test.
  • Quantified Aβ plaque burden, glial cell activation (microglia, astrocytes), cytokine levels, and synaptic markers.

Main Results:

  • LRRK2 deficiency in 5xFAD mice improved learning and memory compared to 5xFAD controls.
  • Reduced cerebral and hippocampal Aβ plaque burden and decreased glial activation were observed in 5xFAD;LRRK2-/- mice.
  • Absence of LRRK2 preserved synaptic structure, reduced neuroinflammation, and enhanced microglial phagocytosis of Aβ.

Conclusions:

  • LRRK2 plays a critical role in Aβ pathology, glial responses, and neuronal dysfunction in the 5xFAD mouse model.
  • Genomic blockade of LRRK2 can reprogram microglial responsivity, mitigating neuropathological and behavioral deficits in AD.
  • LRRK2 inhibition offers a potential therapeutic strategy for Alzheimer's disease by modulating neuroinflammation and synaptic integrity.